TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease
Year: 2013
Type: article
Study design: Observational Study
Abstract: BACKGROUND: A rare variant in the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) gene has been reported to be a genetic risk factor for Alzheimer's disease by two independent groups (Odds ratio between 2.9-4.5). Given the key role of TREM2 in the effective phagocytosis of apoptotic neuronal cells by microglia, we hypothesized that dysfunction of TREM2 may play a more generalized role in neurodegeneration. With this in mind we set out to assess the genetic association of the Alzheimer's disease-related risk variant in TREM2 (rs75932628, p.R47H) with other related neurodegenerative disorders. RESULTS: The study included 609 patients with frontotemporal dementia, 765 with amyotrophic lateral sclerosis, 1493 with Parkinson's disease, 772 with progressive supranuclear palsy, 448 with ischemic stroke and 1957 controls subjects free of neurodegenerative disease. A significant association was observed for the TREM2 p.R47H substitution in susceptibility to frontotemporal dementia (OR = 5.06; p-value = 0.001) and Parkinson's disease (OR = 2.67; p-value = 0.026), while no evidence of association with risk of amyotrophic lateral sclerosis, progressive supranuclear palsy or ischemic stroke was observed. CONCLUSIONS: Our results suggest that the TREM2 p.R47H substitution is a risk factor for frontotemporal dementia and Parkinson's disease in addition to Alzheimer's disease. These findings suggest a more general role for TREM2 dysfunction in neurodegeneration, which could be related to its role in the immune response.
Source: Molecular Neurodegeneration
Authors: Sruti Rayaprolu, Bianca Mullen, Matt Baker, Timothy Lynch, Elizabeth Finger, William W Seeley, Kimmo J Hatanpaa, Catherine Lomen-Hoerth, Andrew Kertesz, Eileen H Bigio, Carol Lippa, Keith A Josephs, David S Knopman, Charles L White, Richard Caselli, Ian R Mackenzie, Bruce L Miller, Magdalena Boczarska-Jedynak, Grzegorz Opala, Anna Krygowska-Wajs, Maria Barcikowska, Steven G Younkin, Ronald C Petersen, Nilüfer Ertekin-Taner, Ryan J Uitti, James F Meschia, Kevin B Boylan, Bradley F Boeve, Neill R Graff-Radford, Zbigniew K Wszolek, Dennis W Dickson, Rosa Rademakers, Owen A Ross
Institutions: Mayo Clinic in Florida, University College Dublin, Mater Misericordiae University Hospital, Western University, University of California, San Francisco, The University of Texas Southwestern Medical Center, Northwestern University, Drexel University, Mayo Clinic, Mayo Clinic in Arizona, University of British Columbia, Medical University of Silesia, Jagiellonian University, Mossakowski Medical Research Institute, Polish Academy of Sciences, Polish Academy of Sciences
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,090
Awards: Neurobiology of Alzheimer's Disease and Aging, Plasma AB as a Surrogate Genetic Marker for LOAD, G3023763630, Understanding the role of MAPT in Parkinsonian disorders, Einstein Aging Study, Progranulin: Mutation and Regulation in Neurodegenerative disease, Understanding the role of TDP-43 in Alzheimer’s disease and FTLD, Genome wide association study of gene expression levels in Alzheimer's disease, Progranulin, TDP-43 and Cell Death, ISGS: The Ischemic Stroke Genetics Study, Genetics and Molecular Biology of Parkinsonism, Alzheimer's Disease Core Center, G8800094791, Frontotemporal Dementia: Genes, Images, and Emotions, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W2132884035
